These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35764936)

  • 21. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
    Qun W; Tao Y
    Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids.
    Fujiwara H; Takahara N; Tateishi K; Tanaka M; Kanai S; Kato H; Nakatsuka T; Yamamoto K; Kogure H; Arita J; Nakai Y; Kasuga M; Ushiku T; Hasegawa K; Koike K
    Surg Oncol; 2020 Dec; 35():484-490. PubMed ID: 33126085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
    Sahin IH; Tan E; Kim R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
    Braun S; McSheehy P; Litherland K; McKernan P; Forster-Gross N; Bachmann F; El-Shemerly M; Dimova-Dobreva M; Polyakova I; Häckl M; Zhou P; Lane H; Kellenberger L; Engelhardt M
    Expert Opin Investig Drugs; 2021 Nov; 30(11):1071-1080. PubMed ID: 34698609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
    Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
    Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel targeted treatment options for advanced cholangiocarcinoma.
    Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
    Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
    Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
    Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
    Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells.
    Zhou G; Lieshout R; van Tienderen GS; de Ruiter V; van Royen ME; Boor PPC; Magré L; Desai J; Köten K; Kan YY; Ge Z; Campos Carrascosa L; Geuijen C; Sprengers D; van der Laan LJW; Verstegen MMA; Kwekkeboom J
    Br J Cancer; 2022 Sep; 127(4):649-660. PubMed ID: 35597867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
    Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
    J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting FGFR inhibition in cholangiocarcinoma.
    Goyal L; Kongpetch S; Crolley VE; Bridgewater J
    Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives.
    Gönül Geyik Ö; Anichini G; Ulukaya E; Marra F; Raggi C
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
    Hidalgo M; Amador ML; Jimeno A; Mezzadra H; Patel P; Chan A; Nielsen ME; Maitra A; Altiok S
    Mol Cancer Ther; 2006 Jul; 5(7):1895-903. PubMed ID: 16891476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 38. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cyclin‑dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.
    Yamamura M; Sato Y; Takahashi K; Sasaki M; Harada K
    Oncol Rep; 2020 Jan; 43(1):306-317. PubMed ID: 31746435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
    Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
    Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.